*Plasmodium falciparum* (*Pf*) and *P. vivax* (*Pv*) infections cause significant morbidity and mortality worldwide ([@bib45]). The scaling up of control methods, including water and vector control, intermittent preventive therapies ([@bib20]), indoor residual spraying ([@bib21]), and artemisinin combination therapies ([@bib5]), have reduced the incidence of *Pf* but not *Pv* malaria in many parts of the world ([@bib22]; [@bib15]; [@bib23]). Moreover, antimalarial drug resistance continues to emerge and malaria remains a major public health problem ([@bib38]). A malaria vaccine would represent the most cost-effective strategy to tackle resistance and protect humans from this disease. Consequently, numerous candidate vaccines are in development for *Pf* and *Pv* malaria ([@bib28]) but an effective vaccine remains elusive. Importantly, *Pf* and *Pv* infections impair the generation of recall cellular ([@bib44]) and humoral responses ([@bib46]) affecting the generation of any type of vaccine immunity. Given the central role of DCs in directing primary and vaccine-induced immune responses ([@bib3]), improved understanding of DC biology during acute malaria is paramount to improve vaccination outcomes.

Circulating DCs are particularly important as they replenish tissue-residing DCs and shape immune responses in vivo ([@bib3]). These cells can be identified as mononuclear cells expressing MHC-II molecules (HLA-DR) but lacking common lineage markers ([@bib36]). This blood DC compartment includes two different subsets discernible into myeloid DC (mDC) or plasmacytoid DC (pDC) based on their reciprocal expression of CD11c or CD123 antigens ([@bib34]). Moreover, mDC can be further subdivided into three subtypes based on the respective expression of CD141, CD16, and CD1c antigens ([@bib26]; [@bib17]). Despite their importance, most studies have only assessed blood DC's numerical phenotype and few functional studies have been reported to date. Numerical characterizations indicate that children with *Pf* display less activated mDC during acute uncomplicated infection ([@bib41]) yet increased numbers of mDC during severe infection ([@bib43]). Adults with *Pf* exhibit reduced pDC during acute uncomplicated, severe ([@bib27]), or pregnancy malaria ([@bib11]). Similarly, adults infected with *Pv* display reduced mDC and pDC numbers ([@bib16]). We have also demonstrated numerical blood DC reductions and increased apoptosis before patent parasitemia in healthy donors undergoing an experimental low-dose *P. falciparum* challenge ([@bib47]). Further functional characterization, in contrast, has mainly been undertaken using in vitro or murine DC models ([@bib42]; [@bib25]; [@bib12]; [@bib4]). However, rodent DCs or DCs generated in vitro after prolonged culture with cytokines are unlikely to reflect the functional status of human DC populations circulating in vivo.

To address these questions, evaluate the role of different *Plasmodium* species on circulating DC, and determine the type and duration of DC impairment after antimalarial treatment, we performed cross-sectional and longitudinal assessments of all circulating DC subsets during uncomplicated *Pf* and *Pv* including convalescent *Pf* infection in 67 Papuan adults. Results were compared with a cohort of 17 malaria-exposed uninfected and asymptomatic Papuan adults. Given the low frequency of blood DC and restricted volumes that could be taken from patients, subcohorts were used for the various analyses. Our results demonstrate that the marked loss of functional DC in the peripheral circulation of patients with *Pf* or *Pv* malaria is associated with significant levels of spontaneous DC apoptosis. Impaired viability and numerical changes also correlate with functional impairment in the ability of DCs to up-regulate costimulatory and MHC-class II molecules as well as antigen uptake and presentation to CD4 T cells. Interestingly, elevated and sustained levels of plasma IL-10, as observed in patients with *Pf* or *Pv*, were implicated in the induction of DC apoptosis. As such, DC apoptosis was reversed upon IL-10 blockade and DC function recovered completely after completion of antimalarial treatment and normalization of IL-10 levels by convalescence. Our data provide key information on the mechanisms behind blood DC suppression during acute malaria and will assist in developing better strategies to harness DC's immunotherapeutic potential and improve vaccination outcomes.

RESULTS
=======

Study cohort
------------

42 adult Papuans with acute uncomplicated *Pf* malaria, 25 adult Papuans with acute *Pv* malaria, and 17 uninfected malaria-exposed Papuan adults were included in the study. 10 of the 42 patients with *Pf* malaria were also assessed at days 7 and 28 after antimalarial treatment. There was no significant difference in the age between groups although there were fewer female volunteers in the uninfected group ([Table 1](#tbl1){ref-type="table"}). Median peripheral parasitemia was similar in acute *Pf* and *Pv* malaria patients, but only *Pf* patients had detectable plasma histidine-rich protein II (HRP2). No peripheral parasitemia or HRP2 was detected in any *Pf* patient at days 7 or 28 after treatment.

###### 

Study cohort

         Subjects   Age                Sex     Parasites/µl           HRP2                                                Temperature
  ------ ---------- ------------------ ------- ---------------------- --------------------------------------------------- ---------------------
                    *median* (*IQR*)   *M/F*   *median* (*IQR*)       *median ng/ml* (*IQR*)                              *median °C* (*IQR*)
  *Pf*   42         23 (18--35)        27/15   5,655 (533--18,250)    107 (1.06--9.28)[a](#tblfn1){ref-type="table-fn"}   36.2 (36.1--37.9)
  *Pv*   25         23 (19--31)        9/16    3,207 (1,020--8,067)   n.d.                                                36.6 (36.3--37.1)
  U      17         27 (20--24)        14/3    n.d.                   n.d.                                                36 (35.5--36.3)

36 subjects. 10 of the 42 *Pf* patients were analyzed at days 7 and 28 after treatment. No peripheral parasitemia or HRP2 was detected on any *Pf* patient at days 7 or 28 after treatment. There were no significant differences between any of these groups. n.d., not detected. U, uninfected.

Subset distribution of DC in patients with malaria
--------------------------------------------------

The blood DC compartment can be identified by flow cytometry as Lin^−^HLA-DR^+^ cells ([@bib39]). This population includes two different subsets distinguished into myeloid DC (mDC) and plasmacytoid DC (pDC) lineages ([@bib34]). Because previous studies suggest dissimilar changes in the frequency of these subsets in acute malaria ([@bib43]; [@bib11]; [@bib16]), we set out to carefully analyze the blood DC compartment in a cohort of 45 patients with acute *Pf* or *Pv* malaria ([Fig. 1 A](#fig1){ref-type="fig"}). Our data demonstrate a significant reduction in absolute counts of mDC (CD11c^+^) and pDC (CD123^+^) concurrent with the marked accumulation of HLA-DR^+^ immature cells (DR^+^IC) in patients with acute malaria ([Fig. 1 B](#fig1){ref-type="fig"}). These immature cells lacked expression of CD11c or CD123 markers yet expressed high levels of the HLA-DR antigen ([@bib29]). Interestingly, this immature population represented only 16.8 ± 2.0% of the blood DC compartment in uninfected donors, while representing a much larger proportion in patients with *Pv* (38.6 ± 3.4%) or *Pf* (46.7 ± 1.8%) infection. The reduction in DC counts was, however, not generalized to other leucocytes. As such, lymphocyte counts were only mildly (not significantly) reduced, monocyte counts were comparable, and neutrophil counts were only marginally increased (not significantly) compared with uninfected donors ([Fig. 1 B](#fig1){ref-type="fig"}).

![**Altered blood DC subset distribution in malaria patients.** (A) Peripheral blood DCs were identified as Lin^−^HLA-DR^+^ cells and analyzed for the expression of CD11c (y axis) and CD123 (x axis) by flow cytometry. The gating strategy for mDC, pDC, and a minor population of HLA-DR^+^ immature cells (DR^+^IC) is shown. Representative dot plots of the blood DC subset distribution in uninfected control and *Pf* or *Pv* patients are shown. Numbers indicate the percentage of cells within each gate. (B) Blood leukocyte counts including lymphocyte, monocyte, neutrophil, mDC, pDC, and DR^+^IC were estimated in a cohort of 45 patients with malaria (*Pv*, *n* = 19; *Pf*, *n* = 26) and compared with uninfected controls (U, *n* = 12). Absolute mDC, pDC, and DR^+^IC counts are expressed as 10^6^/liter and all other counts are expressed as 10^9^/liter. Box plots include means, standard deviations, and ranges. Significant differences compared with uninfected controls are indicated as \*\*\*, P \< 0.001.](JEM_20121972_Fig1){#fig1}

Given that mDCs can be further subdivided into three subtypes based on their respective expression of CD141, CD16, and CD1c antigens ([@bib26]; [@bib17]), numerical characterization of these mDC subsets was also undertaken. Our data confirmed reduced counts of CD141^+^DC, CD1c^+^DC, and CD16^+^DC in patients with acute *Pf* and *Pv* malaria ([Fig. 2 A](#fig2){ref-type="fig"}). Although individual analyses revealed only significant reductions of CD1c^+^DC in *Pf* and CD16^+^DC in *Pv*, composite analyses of all malaria patients (*Pv* plus *Pf*) confirmed significantly reduced counts (P \< 0.05) for all mDC subtypes, suggesting a sample size effect.

![**Altered mDC subset distribution in malaria patients.** (A) mDCs (mDC, CD11c^+^ CD123^+^) were analyzed by flow cytometry for expression of CD141, CD1c, and CD16. DCs were gated as shown, and the populations were enumerated in the blood of 12 patients with malaria (*Pv*, *n* = 6; *Pf*, *n* = 6) and uninfected controls (U, *n* = 5). Data are expressed as cells/µl. Box plots include means, standard deviations, and ranges. Significant differences compared with uninfected controls are indicated as \*, P \< 0.05. (B) In a cohort of *Pv* (*n* = 5) and uninfected (*n* = 5) individuals, lineage-positive HLA-DR^+^ cells were analyzed for expression of CD11c and CD123 (DC), CD79a (B-cells), and CD11b (monocytes). Representative FACS plot from one *Pv* patient shown.](JEM_20121972_Fig2){#fig2}

To confirm that other DC subpopulations induced during inflammatory settings were not excluded by confining our analyses to the Lin^−^HLA-DR^+^ population, characterization of the Lin^+^HLA-DR^+^ population was undertaken in five *Pv* patients ([Fig. 2 B](#fig2){ref-type="fig"}) compared with five uninfected controls. This confirmed the minimal proportion of DCs (\<2%) and the rather large proportion of B cells (CD79a^+^ cells) and monocytes (CD11b^+^ cells) within this gate in malaria patients and uninfected donors (*Pv*: B cells, 59 ± 18%; monocytes, 30 ± 5% vs. uninfected: B cells, 68 ± 10%; monocytes, 35 ± 8%). These results confirm that in patients with acute malaria, the marked reduction in Lin^−^HLA-DR^+^ cells in the peripheral circulation reflects significant reductions in all DC numbers (mDC subsets and pDC) and the concurrent accumulation of immature cells (DR^+^IC).

Spontaneous apoptosis of DC in patients with malaria
----------------------------------------------------

To determine whether reduced viability accounted for some of the changes observed in the DC compartment, we assessed spontaneous apoptosis in blood DC ex vivo. To include all cells undergoing apoptosis while eliminating cellular debris, gating was set as described in [Fig. 3 A](#fig3){ref-type="fig"}. Blood DCs were identified as Lin^−^HLA-DR^+^ cells and apoptosis was estimated using Annexin-V. As shown in [Fig. 3 B](#fig3){ref-type="fig"}, the minimal proportion of spontaneously apoptotic blood DC in uninfected donors was significantly increased in patients with *Pv* or *Pf* infection. Interestingly, apoptosis was mostly evident in DCs (mDC and pDC) as opposed to immature cells (DR^+^IC), partly explaining the large accumulation of DR^+^IC in patients with acute malaria ([Fig. 3 C](#fig3){ref-type="fig"}). Other antigen-presenting cells, such as B cells (CD19^+^) or monocytes (CD14^+^), displayed no significant apoptosis in patients with *Pv* (CD19^+^AnnexinV^+^: 6.4 ± 2.1%; and CD14^+^AnnexinV^+^: 7.3 ± 3.5%) or *Pf* (CD19^+^AnnexinV^+^: 5.4 ± 3.1%; and CD14^+^AnnexinV^+^: 8.3 ± 2.3%) compared with uninfected controls (CD19^+^AnnexinV^+^: 5.7 ± 5.2%; and CD14^+^AnnexinV^+^: 8.3 ± 3.4%). These data suggest that in acute malaria, a process of specific DC suppression occurs whereby functional DCs are induced to undergo apoptosis while circulating in the blood.

![**Spontaneous apoptosis of blood DC in malaria patients.** Blood DC from patients with malaria (*Pv*, *n* = 19; *Pf*, *n* = 26) and uninfected matched controls (U, *n* = 12) were analyzed for apoptosis by flow cytometry. (A) Cells were gated on viable mononuclear cells (R1), which were further gated on 7-AAD--negative cells (R2). Blood DCs were identified as Lin^−^HLA-DR^+^ cells (R3). Representative dot plots are shown. (B) Apoptosis in blood DC from uninfected donors (gray) and patients with malaria (black) was determined using Annexin-V binding assays. In all experiments, each patient was tested in parallel with at least one uninfected donor. Representative histograms and summary of apoptosis data (mean ± SEM) are shown. (C) DC (mDC plus pDC) and DR^+^IC in uninfected donors and malaria patients were evaluated for apoptosis by Annexin-V staining. Numbers indicate the percentage of cells that are positive for Annexin-V. Statistically significant differences between uninfected controls and patients are shown. \*\*\*, P \< 0.001.](JEM_20121972_Fig3){#fig3}

Impaired phenotype and function of DC in patients with malaria
--------------------------------------------------------------

Next, we set out to determine if the reduced viability of blood DC was associated with phenotypic or functional abnormalities. Because expression of MHC II and costimulatory molecules has been correlated to DC's immunostimulatory capacity, first we evaluated the expression of CD83, CD86, and HLA-DR in patients with acute *Pf* or *Pv* malaria. As shown in [Fig. 4 A](#fig4){ref-type="fig"}, ex vivo expression (gray histograms) of CD83, CD86, and HLA-DR in blood DCs from *Pv* or *Pf* patients was comparable to uninfected controls. However, upon overnight incubation (black histograms), blood DCs from *Pv* or *Pf* patients showed markedly reduced ability to up-regulate expression of costimulatory and HLA-DR molecules ([Fig. 4, A and B](#fig4){ref-type="fig"}). Functional assessment also demonstrated significant DC impairment in malaria patients. Here, blood DCs from *Pv* or *Pf* patients had a markedly reduced ability to take-up particulate antigens ([Fig. 4 C](#fig4){ref-type="fig"}) and were poor stimulators of allogeneic CD4 T cell proliferation ([Fig. 4 D](#fig4){ref-type="fig"}) and Th1 cytokine secretion (see [Fig. 8 B](#fig8){ref-type="fig"}). As shown in [Fig. 4 C](#fig4){ref-type="fig"}, impaired antigen uptake was evident in DC (mDC and pDC) as well as in immature cells (DR^+^IC), although less markedly, explaining the overall dysfunction of all Lin^−^DR^+^ populations in patients with malaria. These data demonstrate that the impairment of blood DC in acute malaria affects key aspects of DC function, including maturation (up-regulation of costimulatory and MHC class II molecules), ability to capture antigen, and adequate stimulation of allogeneic CD4 T cell proliferation and cytokine secretion.

![**Impaired phenotype, antigen uptake, and stimulatory capacity in DC from malaria patients.** (A) Expression of the costimulatory molecules CD83, CD86, and HLA-DR was analyzed on blood DC in a cohort of 45 patients with malaria (*Pv*, *n* = 19; *Pf*, *n* = 26) compared with uninfected controls (U, *n* = 12) directly ex vivo (gray histograms) or after overnight incubation (black histograms) without exogenous cytokines. Representative histograms are shown. (B) Summary of phenotypic analysis (mean ± SEM) for each antigen expressed as ΔMFI (*y* axis) between cultured and fresh samples. (C) Blood DCs from uninfected donors (U, *n* = 12) or patients with malaria (*Pv*, *n* = 19; *Pf*, *n* = 26) were incubated with FITC-dextran at 4°C (gray) or 37°C (black), and uptake was measured by flow cytometry. Graph shows summary of antigen uptake data (mean ± SEM) presented as ΔMFI (y axis) between test and control for all patients. (D) Blood DC from patients (*Pf*, *n* = 5; *Pv*, *n* = 5) and uninfected volunteers (U, *n* = 5) was tested against allogeneic CD4 T cells from a panel of healthy Australian donors (*n* = 5). CD4 T cells and blood DCs were co-cultured at a 30:1 T/DC ratio. Cells were harvested after 96 h of culture and CD4 T cell proliferation estimated by CFSE dilution. Bars indicate the percentage of CFSE^dim^ CD4 T cells for each stimulatory condition. In all experiments, each patient was tested in parallel with at least one uninfected donor. Results are representative of five separate experiments performed. Statistically significant differences compared with uninfected controls are indicated. \*, P \< 0.05; \*\*\*, P \< 0.001.](JEM_20121972R_Fig4){#fig4}

Central role for IL-10 in induction of DC apoptosis during malaria
------------------------------------------------------------------

We also set out to assess possible mechanisms responsible for the marked levels of blood DC apoptosis in patients with malaria. Given that no significant apoptosis was observed in uninfected donors and a direct cytopathic effect of the parasite on DC has been excluded ([@bib40]; [@bib37]; [@bib12]), we hypothesized that apoptosis related to the inflammatory response during infection rather than to the parasite itself. To examine this hypothesis, first we evaluated levels of proinflammatory cytokines in plasma of all patients with acute malaria. We found significantly elevated levels of inflammatory cytokines, including IL-2, IL-4, IFN-γ, TNF, IL-6, and IL-10 in all patients with acute *Pv* or *Pf* infection ([Fig. 5 A](#fig5){ref-type="fig"}). Interestingly, IL-2, IL-4, and IFN-γ levels corrected to baseline levels by day 7 (at which time parasites had cleared), whereas elevation of TNF, IL-6, and particularly IL-10 persisted beyond this point. Moreover, levels of plasma IL-10 (but not IL-6 or TNF) correlated with the extent of blood DC apoptosis ([Fig. 5 B](#fig5){ref-type="fig"}) yet no significant correlation was found between parasitemia or plasma HRP2 and either DC numbers or apoptosis (not depicted). This evidence suggested a key role for IL-10 in blood DC apoptosis during acute infection.

![**Profile of cytokines in plasma of patients with malaria.** (A) The indicated plasma cytokines were measured by CBA assay in samples from *Pf* patients (*n* = 10) at days 0 (D0), 7 (D7), and 28 (D28) after antimalarial drug treatment and compared with patients with acute *Pv* (*n* = 19) or uninfected donors (U, *n* = 12). Summary of cytokine levels are presented as mean ± SEM for each cytokine. Significant differences compared with uninfected controls are indicated as \*, P \< 0.05; \*\*, P \< 0.01; and \*\*\*, P \< 0.001. (B) Correlation between the percentage of blood DC undergoing apoptosis (x axis) and cytokine levels for IL-6, TNF, and IL-10 (y axis) in 45 patients with acute malaria (*Pf*, *n* = 26 and *Pv*, *n* = 19). Spearman's Rank Test, R = 0.60, P \< 0.0001 for IL-10; R = −0.14, P = 0.35 for IL-6; and R = −0.07, P = 0.6 for TNF.](JEM_20121972R_Fig5){#fig5}

Interestingly, sustained exposure of DC to high levels of IL-10 during their maturation has been associated with induction of apoptosis ([@bib6]). Therefore, we set out to directly evaluate the role of plasma IL-10 from malaria patients on DC survival in vitro. For this purpose, healthy DCs were induced to mature with LPS and exposed to recombinant human IL-10 or plasma samples from either uninfected donors containing low levels of IL-10 (mean 58.6 pg/ml, *n* = 3) or from patients with *Pf* (*n* = 3) or *Pv* (*n* = 3) containing high levels of IL-10 (*Pf*: mean 602.6 pg/ml; *Pv*: mean 353.8 pg/ml). First, we confirmed the proapoptotic effect of high and sustained levels of rhIL-10 on healthy maturing blood DC ([Fig. 6 A](#fig6){ref-type="fig"}) as previously reported ([@bib6]). More importantly, we found that exposure of healthy maturing DC (*n* = 5) to plasma from *Pf* or *Pv* patients resulted in a significant proportion of DC apoptosis ([Fig. 6 A](#fig6){ref-type="fig"}). To further confirm the role of IL-10 in this process, specific IL-10 blocking was undertaken. As shown individually in [Fig. 6 A](#fig6){ref-type="fig"}, and summarized in [Fig. 6 B](#fig6){ref-type="fig"}, blockade of rhIL-10 or infected plasma IL-10 prevented a comparably large proportion (mean rhIL-10: 63% vs. *Pf* plasma: 53% vs. *Pv* plasma: 52%) of blood DC from undergoing apoptosis. These data confirmed the central role of IL-10 rather than other plasma cytokines in affecting DC survival and indicate that elevated levels of plasma IL-10 to the extent observed in patients with *Pf* or *Pv* can induce apoptosis in a significant proportion of blood DC.

![**IL-10 induces apoptosis of maturing blood DC.** (A) Blood DCs from healthy Australian donors (*n* = 5) were induced to mature by 24 h incubation with LPS and subsequently exposed to either 500 pg/ml of exogenous recombinant human IL-10 (LPS + IL-10) or 50% (vol/vol) plasma samples from uninfected volunteers containing low levels of IL-10 (*n* = 3, mean 58.6 pg/ml, U Plasma) or high levels of IL-10 from *Pf* (*n* = 3; mean 602.6 pg/ml, Pf plasma) or *Pv* (*n* = 3; mean 353.8 pg/ml, Pv plasma) patients with or without anti--IL-10R antibodies. Representative histograms from three donors are shown. Numbers indicate the percentage of apoptotic (Annexin-V^+^) blood DC in each culture. Results are representative of three separate experiments. (B) Graph shows summary data of all donors. Statistically significant differences between samples exposed to blocking (anti--IL-10R) and nonblocking (Isotype) antibodies as well as between U plasma and *Pf* or *Pv* plasma are indicated. Error bars show SEM. \*, P \< 0.05; \*\*\*\*, P \< 0.0001.](JEM_20121972_Fig6){#fig6}

Effect of antimalarial treatment on DC phenotype and function
-------------------------------------------------------------

Finally, to determine whether antimalarial treatment could reverse the impaired phenotype and viability of blood DC, we performed a longitudinal assessment in a cohort of 10 patients with *Pf* infection. In these patients, blood DCs were analyzed during acute malaria at day 0 and also at days 7 and 28 after successful antimalarial drug treatment. We have demonstrated elsewhere that artemisinin combination therapy drugs do not affect blood DC phenotype or function ([@bib47]). Here, blood DCs were analyzed for their subset distribution, viability, phenotype, and ability to take up antigen and stimulate allogeneic CD4 T cells. We found that patients with *Pf* infection exhibited a delayed correction in the numbers of mDC and pDC. In fact, mDC, pDC, and DR^+^IC counts only corrected to levels comparable to uninfected donors by day 28 ([Fig. 7, A and B](#fig7){ref-type="fig"}). Similarly, the proportion of blood DC undergoing apoptosis remained significantly elevated by day 7 and only returned to baseline levels equivalent to uninfected individuals by day 28 ([Fig. 7, C and E](#fig7){ref-type="fig"}). Antigen uptake also demonstrated a delayed improvement with efficient uptake comparable to uninfected donors only achieved by day 28 ([Fig. 7, D and G](#fig7){ref-type="fig"}). Up-regulation of the costimulatory phenotype followed a more rapid trend, with adequate expression of CD83 and CD86 achieved by day 7 yet efficient up-regulation in the expression of HLA-DR being delayed until day 28 ([Fig. 7 F](#fig7){ref-type="fig"}).

![**Reversal of DC dysfunction after antimalarial treatment.** (A and B) Blood DCs were analyzed during acute *Pf* malaria at day 0 (D0) and also at days 7 (D7) and 28 (D28) after antimalarial treatment in a cohort of 10 patients and compared with uninfected volunteers (U, *n* = 12). In all experiments, each patient was tested in parallel with at least one uninfected volunteer. The blood DC compartment was analyzed for absolute counts of mDC, pDC, and DR^+^IC (10^6^/liter; A) and blood DC subset distribution. (B) Representative dot plots of one uninfected control as well as one patient assessed at days 0 (D0), 7 (D7), and 28 (D28) are shown. Values indicate percentage of cells within respective gates. (C) Summary of blood DC apoptosis data (mean ± SEM). (D) Summary of antigen uptake (FITC-Dextran) data assessed as the difference between uptake at 37°C (test) or 4°C (control) expressed as ΔMFI (mean ± SEM). (E) Representative histograms of apoptosis from one patient at days 0 (D0), 7 (D7), and 28 (D28) compared with one uninfected control. Values indicate percentage of Annexin-V--positive cells. (F) Summary of phenotypic maturation estimated by up-regulation in expression of CD83, CD86, and HLA-DR expressed as ΔMFI (mean ± SEM). (G) Representative histograms of antigen uptake from one patient at days 0 (D0), 7 (D7), and 28 (D28) compared with one uninfected control. Gray histograms indicate uptake at 4°C (control) and black histograms represent uptake at 37°C (test). Values indicate uptake as ΔMFI between cultured and fresh samples. Statistically significant differences compared with uninfected volunteers are indicated as \*, P \< 0.05; \*\*, P \< 0.01; and \*\*\*, P \< 0.001.](JEM_20121972_Fig7){#fig7}

In keeping with these findings, characterization of the function and phenotype of T cells induced by stimulation with malaria DC revealed impaired allogeneic CD4 T cell proliferation ([Fig. 8 A](#fig8){ref-type="fig"}) and inadequate induction of Th1 cytokines ([Fig. 8 B](#fig8){ref-type="fig"}). Interestingly, no significant differences in the expression of T cell activation markers CD25 (*Pf*: 48 ± 12% vs. U: 55 ± 12%), CD27 (*Pf*: 70 ± 8% vs. U: 73 ± 12%), or CD69 (*Pf*: 7 ± 4% vs. U: 9 ± 5%) was evident in cultured T cells, suggesting that malaria DCs were able to activate but not properly stimulate Th1 cell function in vitro. Reversal of such DC impairment, however, was evident in DCs collected by day 28 after treatment ([Figs. 7](#fig7){ref-type="fig"} and [8](#fig8){ref-type="fig"}). Interestingly, plasma IL-10 showed parallel kinetics to DC dysfunction with low IL-10 levels comparable to uninfected donors attained by day 28 after treatment ([Fig. 5](#fig5){ref-type="fig"}). Although these results suggest a protracted period of DC impairment, they confirm that full recovery of functional and competent blood DC is only achievable after antimalarial drug treatment and normalization of IL-10 levels.

![**Recovery of DC allostimulatory capacity after antimalarial treatment.** (A) Naive allogeneic CD4 T cells purified from a panel of healthy Australian donors (*n* = 5) were co-cultured with blood DC from malaria patients at day 0, 7, or 28 (*n* = 8) or uninfected controls at a 30:1 T/DC ratio (*n* = 12). Cells were harvested after 96 h of culture and CD4 T cell proliferation estimated by CFSE dilution (x axis). Representative histograms are shown with numbers indicating the percentage of CFSE^dim^ CD4 T cells for each stimulatory condition. The representative pairs giving maximal responses for three different T cell donors are shown. In all experiments, each patient was tested in parallel with at least one uninfected volunteer. (B) Supernatants from cultures in A were harvested after 72 h and levels of IL-2, TNF, IFN-γ, IL-6, IL-4, and IL-10 estimated using CBA assay by FACS. Box plots include means, standard deviations, and ranges. Significant differences compared with uninfected controls are indicated as \*, P \< 0.05. Results are representative of five separate experiments performed.](JEM_20121972_Fig8){#fig8}

DISCUSSION
==========

The aim of this study was to evaluate the blood DC compartment in patients with *Pf* or *Pv* malaria to identify factors suitable for clinical implementation (i.e., antimalarial treatment) to improve their function. We focused on the blood DC compartment because this population directly reflects the natural biology of immune responses occurring in vivo. Therefore, detailed cross-sectional and longitudinal assessments in 67 patients with acute uncomplicated *Pf* or *Pv*, as well as convalescent *Pf* malaria, were performed to demonstrate significant and protracted impairment in number, function, and viability of blood DC during acute malaria. More importantly, our results demonstrate that full recovery of functional and competent blood DC is achievable only after adequate antimalarial drug treatment and normalization of IL-10 levels in patients with acute malaria.

Although previous studies have reported changes of blood DC in people with malaria, results have been contradictory and limited functional data are available. Children with severe *Pf* have been reported to exhibit increased numbers of mDC ([@bib43]), whereas adults with *Pf* have reduced pDC during uncomplicated and severe disease ([@bib27]). Adults with *Pv* also appear to have reduced mDC and pDC ([@bib16]; [@bib14]). Our data, examining adults with acute malaria demonstrate the significant and comparable reduction in mDC, including all mDC subsets (CD141^+^DC, CD1c^+^DC, and CD16^+^DC) as well as pDC counts in patients with *Pf* or *Pv* infection. An immature population (DR^+^IC) distinct from the myeloid (mDC) and plasmacytoid (pDC) subtypes also emerged as a significant proportion of the DC compartment. These immature cells are known to express high levels of HLA-DR (100%) and display variable expression of other DC markers like CD2, DC-SIGN, BDCA-4, CD4, or CD1c (3--20%). Similarly, a variable proportion of DR^+^ICs express progenitor antigens like CD7, CD10, CD13, or CD33 (3--20%), myeloid antigens like MPO or CD15 (1--5%), lymphoid markers like CD79a (15--20%), or integrins like CD11b, CD62L, CD41, or CD61 (5--30%), altogether suggesting that multiple small subpopulations of progenitors, as well as immature DCs, coexist in the circulation ([@bib29]). Other reports also indicate increased numbers of immature DCs during uncomplicated malaria in pregnancy ([@bib1]; [@bib11]) and in children ([@bib41]). Although the reduction in functional DC and the accumulation of immature cells had been proposed to contribute to immune dysfunction in malaria ([@bib1]; [@bib11]), the mechanisms behind such changes and their functional consequences had not been investigated in the past. Recently, we demonstrated reduced counts and increased apoptosis of blood DC in healthy volunteers undergoing an experimental low-dose *P. falciparum* challenge ([@bib47]). Here, we expand and complement our data by thoroughly characterizing blood DC phenotype, viability, and function in patients with clinical *Pf* and *Pv* malaria also establishing for the first time that IL-10 is implicated in the process.

Declining blood DC counts could be a direct consequence of increased migration to lymphoid tissues. In this regard, murine malaria models indicate rapid and vigorous DC migration to the spleen after infection ([@bib35]). DC migration in human infection has been more difficult to assess as simultaneous data from blood and lymphoid organs are not available. However, in vitro models demonstrate that exposure of human DC to parasitized red cells increase their expression of chemokine receptors CCR7 and CXCR4 ([@bib27]; [@bib13]), suggesting enhanced lymphoid organ migration during infection. Preliminary data from our laboratory also support this notion and show increased expression of CCR7, CXCR4, and CCR5 in blood DC of patients with *Pf* or *Pv* malaria (unpublished data). Although increased migration to lymphoid organs is likely occurring, its effect on peripheral counts is unclear and a definitive answer will only arise from the simultaneous assessment of DC in blood and lymphoid tissues. Myeloid suppression or impaired production of DC progenitors could also be proposed to explain declining blood DC numbers in human malaria. However, our data on the accumulation of immature cells and similar reports of increased immature DC during maternal human infection ([@bib1]; [@bib11]) or CD34^+^ DC progenitors in blood of children with malaria ([@bib41]) suggest that myeloid suppression is unlikely to be of significance. Finally, impaired viability of blood DC could contribute to declining counts if a significant proportion of cells are programmed to die while in the circulation. Our results not only confirm the latter hypothesis but suggest that the cytokine milieu occurring in vivo is impacting vigorously on the longevity of all blood DC subpopulations during infection.

The physiological significance of this finding is three-pronged. First, circulating DCs are essential for adequate immunity as they continually replenish the pool of tissue-residing DCs. In fact, most circulating DCs are en route from the bone marrow to peripheral and lymphoid tissues or from nonlymphoid tissues to the regional lymph nodes and spleen ([@bib10]). Given that apoptotic cells are rapidly cleared by the reticulo-endothelial system, increased turnover rate of blood DC is likely occurring in these patients. As infection progresses, continual efforts to replace the pool of blood DC from bone marrow imposes pressure on hematopoietic capacity, resulting in the paucity of functional DC ([@bib41]; [@bib1]; [@bib11]; [@bib16]) and the concurrent accumulation of immature cells in the circulation ([@bib1]; [@bib11]). Second, apoptotic DCs are ineffective at inducing immunity ([@bib19]), and this can contribute to systemic immune dysregulation and parasite evasion. Third, apoptosis can relate to the immune response against the parasite rather than a direct cytopathic effect of the parasite, and hence it may be amenable to modification through normalization of the suppressive cytokine environment in which DCs are engaged.

In this regard, cytokines that regulate the inflammatory response, and particularly IL-10, have been suggested to affect blood DC during acute malaria ([@bib43]; [@bib11]). Maturing DCs undergo apoptosis after exposure to high levels of IL-10 ([@bib6]), and a correlation between high IL-10 and reduced DC counts has been suggested for human *Pf* ([@bib43]; [@bib11]) and *Pv* infections ([@bib16]; [@bib14]). Here, we demonstrate for the first time a direct causal relationship between increased levels of plasma IL-10 and blood DC apoptosis in patients with clinical *Pf* or *Pv* infections. In malaria, IL-10 is an important cytokine and immune modulator that strikes a balance between immune protection and immunopathology ([@bib9]). However, sustained exposure of DC to IL-10 can suppress the induction of antiapoptotic genes like *bcl-2*, *bcl-x*, and *bfl-1* at a time of increased sensitivity to viability signals, i.e., during DC maturation ([@bib6]). Additionally, exocrine IL-10 can drive secretion of autocrine IL-10 by DC and other cell types further impacting on cell survival ([@bib8]). In human malaria for example, in vitro--derived DCs exposed to infected erythrocytes fail to secrete IL-12 yet produce increasing levels of IL-10 ([@bib40]). Similarly, in rodent malaria, DCs progressively increase their ability to produce IL-10 and induce an IL-10--dominated T cell response ([@bib25]). Therefore, while controlling immunopathology, the scale of IL-10 exposure throughout the maturation process appears to determine the lifespan of blood DC via mechanisms involving cytokine regulation and antiapoptotic gene modulation.

Although apoptosis and high levels of IL-10 appeared central to DC impairment in the present study, other mechanisms have also been proposed. Earlier studies using in vitro--derived DC indicate that *Plasmodium* can compromise DC via a mechanism involving direct contact through *Pf*EMP1 ([@bib42]). However, more recent evidence using a similar in vitro approach suggests that modulation is independent of parasite contact and rather depends on parasite dose ([@bib12]). Because *Pv*-infected red cells do not express *pf*EMP1 and are minimally cytoadherent, our finding of comparable DC impairment with either parasite would support the contact-independent nature of DC modulation. Other reports also implicate hemozoin in the modulation of DC through TLR-dependent binding ([@bib7]; [@bib24]) and suggest that induction of TLR tolerance is central to DC dysregulation ([@bib25]). In our study, sample limitation precluded direct assessment of blood DC--parasite interactions ex vivo. However, the observations that DC apoptosis and dysfunction persisted beyond parasite clearance (day 7), was in part IL-10 dependent, and normalized by day 28 upon resolution of the cytokine response suggested that DC impairment during clinical disease was primarily related to the immune response against the parasite rather than to the parasite itself. The lack of correlation between baseline parasitemia or plasma HRP2 and either DC numbers or apoptosis also indicated that by the time of presentation with clinical malaria, DC impairment was cytokine driven rather than parasite driven.

Whereas an alteration in the numerical and maturational phenotype of blood DC in acute malaria had been previously described ([@bib16]; [@bib14]), there had only been few reports on the function of blood DC in patients with clinical malaria ([@bib2]) and no longitudinal studies in clinical disease had been described to date. Our cross-sectional assessment in 67 Papuan adults with acute malaria allowed us to demonstrate that the marked changes in blood DC viability were associated with significant impairment in all aspects of DC function (maturation, antigen uptake, and presentation) in patients with either type of parasite. In fact, we show that blood DC from *Pf* and *Pv* patients display impaired ability to up-regulate costimulatory and MHC class II molecules as well reduced antigen uptake and ability to stimulate CD4 T cell proliferation and cytokine secretion. Moreover, upon longitudinal follow up, we demonstrate that parasite clearance and normalization of the cytokine milieu after antimalarial treatment facilitate recovery of fully competent blood DC in patients with malaria.

Therefore, our findings point out that impairment of blood DC number and function, as well as induction of apoptosis, is not species-specific and occurs with the two *Plasmodium* species causing the majority of global malaria. Consequently, our results have significant implications not only for understanding immune dysfunction during malaria but also for the development of effective interventions to improve vaccination outcomes against this disease. In view of the remarkable diversity of immunosuppressive pathways in malaria, any clinical response achieved by vaccination is already considered an achievement. However, to improve responses to any of the current subunit or whole parasite vaccine formulations ([@bib28]), vaccines will need to be combined with other strategies that can offset the suppressive environment in which DCs are primed. Given the protracted nature of the DC dysfunction described here in patients with acute infection and the observation that parasite clearance and normalization of the cytokine milieu after antimalarial treatment facilitate DC recovery, combination strategies will likely be required. Based on the evidence presented here, we propose that vaccination in the context of iterative preventive therapies, pre-vaccination antimalarial treatment, immunization during nontransmission season, or the use of approaches which vigorously stimulate DC and cellular immunity ([@bib30]) should be considered to improve vaccination outcomes for malaria.

MATERIALS AND METHODS
=====================

### Study subjects and samples.

84 highland Papuans were recruited in Timika, a lowland region of Papua, Indonesia, with perennial unstable malaria transmission of both *Pf* and *Pv* ([@bib18]). Subjects were enrolled in trials of chloroquine and sulphadoxine-pyrimethamine or artemisinin combination therapy after providing informed consent ([@bib32],[@bib33]). Individuals with acute uncomplicated malaria---as defined by acute onset of fever within 48 h of enrolment---with no alternative cause identified and parasitemia by microscopically identified *Pf* (*n* = 42) or *Pv* (*n* = 25) were included in the study. No patients with mixed infection were included. For all patients, venous blood was collected at the time of presentation. Additionally, in 10 *Pf* patients with clinical and parasitological cure, venous blood was also collected at 7 and 28 d after successful antimalarial drug treatment with chloroquine plus sulfoadioxine-pyrimethamine or artemisinin combination therapy (ACT). Malaria-exposed uninfected subjects (*n* = 17) served as controls; these were resident in the Timika district for at least 2 yr and had no fever or symptoms of malaria within the preceding 2 wk as previously described ([@bib31]). The studies were approved by the Ethics Committees of the National Institute of Health Research and Development, Ministry of Health, Jakarta, Indonesia; the Menzies School of Health Research, Darwin, Australia; and the Queensland Institute of Medical Research, Brisbane, Australia.

### Antibodies and reagents.

The following mAbs were used in this study: CD3, CD14, CD19, CD20, CD56, CD34, HLA-DR, CD86, CD25, CD27, CD69, CD79a, and CD11b and IgG1, IgG2a, and IgG2b isotype controls (BD); and HLA-DR, CD83, CD19, and IgG1 isotype control (Beckman Coulter). All antibodies were used as FITC, PE, biotin, APC, or PE-Cy5 conjugated. Complete media included RPMI 1640 supplemented with 10% FCS, 100 U/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine, 25 mM Hepes, and nonessential amino acids (Gibco). 10 ng/ml LPS and 1 mg/ml FITC-Dextran were purchased from Sigma-Aldrich.

### Flow cytometry, antigen uptake, and mixed leukocyte reaction.

PBMCs were stained with the lineage mixture (CD3, CD14, CD19, CD20, CD56, and CD34) and HLA-DR. Flow cytometry (FACS) was used to evaluate DC numbers, phenotype, antigen uptake, and function. Blood DCs were defined as Lin^−^HLA-DR^+^ cells. Blood DC subsets were identified using CD11c (mDC) and CD123 (pDC) antibodies. mDC subsets were further characterized using CD141, CD1c, and CD16 antigens. Antigen uptake was assessed after cells were incubated (10^7^ cells/ml) for 60 min with FITC-Dextran at either 37°C (test) or 4°C (control). Antigen uptake was calculated as the difference in mean fluorescence intensity (ΔMFI) between the test and control. To assess allostimulatory capacity, PBMCs from patients or uninfected volunteers were individually tested against naive allogeneic CD4 T cells obtained from buffy coats from healthy Australian volunteers (*n* = 5, Australian Red Cross). Naive allogeneic CD4 T cells (\>95% CD4) were purified by negative immunoselection using the naive CD4 T cell isolation kit (Miltenyi Biotec) and labeled using the vibrant CFDA-SE Cell Tracer Kit (Molecular Probes). CD4 T cells were adjusted at 10^5^/well and cultured with DCs from malaria patients or uninfected controls at a 30:1 T/DC ratio in PBMC cultures. In all cases, DC numbers were adjusted based on absolute counts estimated by FACS before culture. Cells were harvested after 96 h of culture and CD4 T cell proliferation estimated by CFSE dilution using MODFIT proliferation software (Verifit Software). Similar results were found for all T/DC ratios. In all experiments, cells were analyzed within 1 h of staining and 5--10 × 10^5^ events were collected within the mononuclear cell gate. Absolute DC counts were calculated from the number of PBMCs/liter of blood as determined by the automated cell counter multiplied by the percentage of DCs determined by FACS. Lymphocyte, monocyte, and neutrophil counts were determined by automated cell counter. Serum and supernatant cytokines were measured using the cytometric bead array (CBA) for human Th1/Th2 cytokine kit (BD). Data were acquired on a FACSCalibur equipped with CellQuestPro and CBA software (BD) according to the manufacturer's instructions.

### Apoptosis and IL-10 assay.

To determine the proportion of apoptotic cells, Annexin-V binding assays were performed according to the manufacturer's instructions (Annexin-V kit; BD). Briefly, PBMCs were adjusted to 10^6^ cells/ml and stained with lineage markers and HLA-DR as above. Cells were washed and resuspended in binding buffer before incubating with Annexin-V and 7-AAD. 7-AAD was added as a viability indicator except when co-labeling for CD11c plus CD123 expression. In all experiments, DC apoptosis was analyzed by FACS within 1 h of staining. The proapoptotic effects of IL-10 on DC were tested as previously described ([@bib6]). In brief, PBMC cultures (10^7^ cells/ml) from healthy adult Australian volunteers (*n* = 5) were incubated in complete medium with 10 ng/ml LPS and either 500 pg/ml rhIL-10 (R&D Systems) or 50% (vol/vol) plasma from patients with *Pf* (*n* = 3; mean IL-10 concentration 602.6 pg/ml) or *Pv* (*n* = 3; mean IL-10 concentration 353.8 pg/ml) for 24 h. Blood DC apoptosis was estimated by Annexin-V staining. Cultures incubated with LPS alone or serum from uninfected volunteers (*n* = 3; mean IL-10 concentration 58.6 pg/ml) served as controls. To neutralize IL-10, 5 µg/ml anti--IL-10R1 mAb or the respective IgG1 isotype control (R&D Systems) was added to cultures as indicated. Doses and incubation times were optimized in preliminary experiments. In all experiments, 5--10 × 10^5^ events were collected within the mononuclear cell gate. Data were acquired on a FACSCalibur and analyzed using CellQuest 3.1 or Summit (Cytomation) software.

### Statistical analysis.

All statistical analyses used Prism 5 (GraphPad Software Inc.). Comparisons of samples to establish statistical significance were determined by the two tailed Student's *t* test or one way analysis of variance (ANOVA), followed by Bonferroni's test. Correlation analyses were performed using Spearman's Rank test. Results were considered to be statistically significant when p-value was \<0.05.
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